What infection types and patient groups are studied in NCT04512345?
NCT04512345 is listed as a clinical-trial record for evaluating tinidazole in the setting of refractory anaerobic bacterial infections. That phrasing typically indicates patients whose anaerobic infection does not respond adequately to standard therapy, but the specific inclusion criteria (for example, confirmed anaerobic pathogens, prior antibiotic failures, and the clinical syndromes allowed) are defined in the trial’s registry entry and supporting documents. If you share the trial’s country/phase or the registry text you’re looking at, I can map those details precisely to the trial’s eligibility criteria.
What does “refractory” mean in this trial’s context?
In clinical-trial registries, “refractory” generally means the infection is resistant to, or has not improved with, usual or earlier treatments. For tinidazole studies, that usually translates into one of these real-world scenarios:
- persistent infection despite prior antimicrobial therapy that would normally cover anaerobes
- recurrence or progression after an earlier course of antibiotics
- intolerance to alternative agents limiting effective treatment options
The exact operational definition (how long prior therapy lasted, what counts as failure, and what clinical measurements are required) comes from the registry’s inclusion criteria.
Is NCT04512345 actually about tinidazole, and what is it comparing?
To answer this accurately, the trial registry needs to be checked for:
- the drug formulation (tinidazole alone vs. combination therapy)
- dosing schedule and route
- comparator (placebo, standard-of-care regimen, or another antibiotic)
- trial phase (safety/efficacy focus differs by phase)
If you paste the NCT registry “Brief Summary,” “Interventions,” or “Arms” section, I’ll translate it into plain language (what tinidazole is being used for, how it’s administered, and what it’s being measured against).
What outcomes does the trial use (response rate, microbiology, or safety)?
Trials in anaerobic bacterial infections usually track outcomes in one or more of these buckets:
- clinical response (improvement in fever, pain, drainage, lesion size, etc.)
- microbiologic response (eradication or reduction of anaerobic organisms)
- time-to-improvement or need for rescue therapy
- safety and tolerability (adverse events, liver tests, and other medication-specific risks)
The registry entry will specify the primary endpoint and the key secondary endpoints, including the timepoints for assessment.
How to find the results or status for NCT04512345
For NCT-linked trials, the registry record usually shows:
- recruiting status (not yet recruiting, recruiting, active/not recruiting, completed)
- study start/end dates
- whether results are posted (and sometimes which dataset is public)
If your goal is the most current information, the registry page is the authoritative starting point for status and posted results.
Risks and safety considerations with tinidazole (what patients usually ask)
Tinidazole is a nitroimidazole class antimicrobial, so clinicians typically watch for class-typical issues such as gastrointestinal effects and neurologic or hypersensitivity reactions in susceptible individuals. Specific trial safety monitoring (e.g., liver function frequency, neurologic symptom screening, exclusion of alcohol use) is defined by the protocol and appears in the registry’s design details.
What to do next if you want the exact protocol details
If you paste any of the following from NCT04512345, I’ll produce a precise, trial-specific “what it tests and what it measures” readout:
- “Brief Summary”
- “Intervention(s)” / “Arms and Interventions”
- “Inclusion Criteria” (or at least the key bullets)
- “Primary Outcome Measure” and “Secondary Outcome Measure”
Sources
No sources were provided in your prompt, and I don’t have enough information here to reliably identify the specific NCT04512345 protocol details (endpoints, phase, arms, and status) without the registry text or links. If you provide the NCT link or pasted registry sections, I can answer with exact specifics.